Innovations in personalised diabetes care and risk management

被引:12
作者
Nijpels, Giel [1 ]
Beulens, Joline W. J. [2 ]
van der Heijden, Amber A. W. A. [1 ]
Elders, Petra J. [1 ]
机构
[1] Amsterdam UMC Locat VUmc, Dept Gen Practice & Elderly Care Med, Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands
[2] Amsterdam UMC Locat VUmc, Dept Epidemiol & Biostat, Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands
关键词
Complications; diabetes; personalised medicine; risk stratification; OLDER-PEOPLE; CLASSIFICATION SYSTEMS; CARDIOVASCULAR-DISEASE; SCREENING FREQUENCY; PREDICTION MODELS; TREATMENT TARGETS; ELDERLY-PATIENTS; FOOT ULCER; TYPE-2; VALIDATION;
D O I
10.1177/2047487319880043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is associated with an increased risk of developing macro and microvascular complications. Nevertheless, there is substantial heterogeneity between people with type 2 diabetes in their risk of developing such complications. Personalised medicine for people with type 2 diabetes may aid in efficient and tailored diabetes care for those at increased risk of developing such complications. Recently, progress has been made in the development of personalised diabetes care in several areas. Particularly for the risk prediction of cardiovascular disease, retinopathy and nephropathy, innovative methods have been developed for prediction and tailored monitoring or treatment to prevent such complications. For other complications or subpopulations of people with type 2 diabetes, such as the frail elderly, efforts are currently ongoing to develop such methods. In this review, we discuss the recent developments in innovations of personalised diabetes care for different complications and subpopulations of people with type 2 diabetes, their performance and modes of application in clinical practice.
引用
收藏
页码:125 / 132
页数:8
相关论文
共 57 条
  • [41] Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes
    Seidu, Samuel
    Kunutsor, Setor K.
    Topsever, Pinar
    Hambling, Clare E.
    Cos, Francesc X.
    Khunti, Kamlesh
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (07) : 1668 - 1679
  • [42] HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups
    Sidorenkov, Grigory
    van Boven, Job F. M.
    Hoekstra, Trynke
    Nijpels, Giel
    Hoogenberg, Klaas
    Denig, Petra
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (08) : 1957 - 1964
  • [43] Evidence-based diabetes care for older people with Type 2 diabetes: a critical review
    Sinclair, A. J.
    Abdelhafiz, A. H.
    Forbes, A.
    Munshi, M.
    [J]. DIABETIC MEDICINE, 2019, 36 (04) : 399 - 413
  • [44] The unmet need for better risk stratification of non-proliferative diabetic retinopathy
    Sivaprasad, S.
    Pearce, E.
    [J]. DIABETIC MEDICINE, 2019, 36 (04) : 424 - 433
  • [45] Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis
    Siwy, Justyna
    Zuerbig, Petra
    Argiles, Angel
    Beige, Joachim
    Haubitz, Marion
    Jankowski, Joachim
    Julian, Bruce A.
    Linde, Peter G.
    Marx, David
    Mischak, Harald
    Mullen, William
    Novak, Jan
    Ortiz, Alberto
    Persson, Frederik
    Pontillo, Claudia
    Rossing, Peter
    Rupprecht, Harald
    Schanstra, Joost P.
    Vlahou, Antonia
    Vanholder, Raymond
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (12) : 2079 - 2089
  • [46] Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study
    Strain, W. David
    Agarwal, Abhijit S.
    Paldanius, Paivi M.
    [J]. AGING-US, 2017, 9 (03): : 769 - 777
  • [47] Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
    Strain, W. David
    Lukashevich, Valentina
    Kothny, Wolfgang
    Hoellinger, Marie-Jose
    Paldanius, Paeivi Maria
    [J]. LANCET, 2013, 382 (9890) : 409 - 416
  • [48] Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
    Stratton, I. M.
    Cull, C. A.
    Adler, A. I.
    Matthews, D. R.
    Neil, H. A. W.
    Holman, R. R.
    [J]. DIABETOLOGIA, 2006, 49 (08) : 1761 - 1769
  • [49] Biomarkers of Diabetic Retinopathy
    Ting, Daniel Shu Wei
    Tan, Kara-Anne
    Phua, Val
    Tan, Gavin Siew Wei
    Wong, Chee Wai
    Wong, Tien Yin
    [J]. CURRENT DIABETES REPORTS, 2016, 16 (12)
  • [50] Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes
    Tofte, N.
    Lindhardt, M.
    Adamova, K.
    Beige, J.
    Beulens, J. W. J.
    Birkenfeld, A. L.
    Currie, G.
    Delles, C.
    Dimos, I.
    Francova, L.
    Frimodt-Moller, M.
    Girman, P.
    Goeke, R.
    Havrdova, T.
    Kooy, A.
    Mischak, H.
    Navis, G.
    Nijpels, G.
    Noutsou, M.
    Ortiz, A.
    Parvanova, A.
    Persson, F.
    Ruggenenti, P. L.
    Rutters, F.
    Rychlik, I.
    Spasovski, G.
    Speeckaert, M.
    Trillini, M.
    von der Leyen, H.
    Rossing, P.
    [J]. DIABETIC MEDICINE, 2018, 35 (10) : 1375 - 1382